3,4-MDO-U-47700

A synthetic opioid analgesic

3,4-MDO-U-47700
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

3,4-MDO-U-47700 is a synthetic opioid analgesic that is structurally related to U-47700, a compound developed in the 1970s by Upjohn for potential use as a painkiller. This compound is part of a class of drugs known as opioids, which are substances that act on opioid receptors to produce morphine-like effects.

Chemical structure and properties

3,4-MDO-U-47700 is characterized by the presence of a methylenedioxy group attached to the phenyl ring, which distinguishes it from its parent compound, U-47700. The chemical structure of 3,4-MDO-U-47700 is defined by the IUPAC name (1R,2R)-2-[(3,4-methylenedioxyphenyl)methylamino]-1-phenylpentan-1-ol.

Pharmacology

As an opioid, 3,4-MDO-U-47700 primarily exerts its effects by binding to the mu-opioid receptor, which is responsible for its analgesic and euphoric properties. The binding affinity and potency of 3,4-MDO-U-47700 at opioid receptors are subjects of ongoing research, as these properties determine its potential for abuse and therapeutic use.

Legal status

Due to its structural similarity to U-47700 and its potential for abuse, 3,4-MDO-U-47700 may be subject to legal restrictions in various jurisdictions. Many synthetic opioids have been classified as controlled substances in an effort to curb their misuse and associated health risks.

Potential risks and side effects

The use of 3,4-MDO-U-47700, like other opioids, carries the risk of opioid addiction, respiratory depression, and overdose. The presence of the methylenedioxy group may also influence its metabolic pathway and toxicity profile, although specific data on 3,4-MDO-U-47700 is limited.

Related pages

• Opioid
• U-47700
• Opioid receptor
• Synthetic opioid